ID: ALA4164713

Max Phase: Preclinical

Molecular Formula: C22H16ClNO5S

Molecular Weight: 441.89

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1cc2ccccc2n1S(=O)(=O)c1ccc(OCc2cccc(Cl)c2)cc1

Standard InChI:  InChI=1S/C22H16ClNO5S/c23-17-6-3-4-15(12-17)14-29-18-8-10-19(11-9-18)30(27,28)24-20-7-2-1-5-16(20)13-21(24)22(25)26/h1-13H,14H2,(H,25,26)

Standard InChI Key:  QDHAZAAJSGGQDF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 441.89

Molecular Weight (Monoisotopic): 441.0438

AlogP: 4.81

#Rotatable Bonds: 6

Polar Surface Area: 85.60

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.43

CX Basic pKa:

CX LogP: 4.75

CX LogD: 1.35

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.46

Np Likeness Score: -1.23

References

1. Wan Y, Dai N, Tang Z, Fang H..  (2018)  Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.,  146  [PMID:29407973] [10.1016/j.ejmech.2018.01.076]

2. Mortenson PN, Erlanson DA, de Esch IJP, Jahnke W, Johnson CN..  (2019)  Fragment-to-Lead Medicinal Chemistry Publications in 2017.,  62  (8): [PMID:30462504] [10.1021/acs.jmedchem.8b01472]

3. Negi A, Murphy PV..  (2021)  Development of Mcl-1 inhibitors for cancer therapy.,  210  [PMID:33333396] [10.1016/j.ejmech.2020.113038]

Source

Source(1):

• Scientific Literature